Updated July 9, 2026: This piece originally described Schedule III rescheduling as a pending, future decision. It was not, by the time this article published. On April 28, 2026, a DEA final order took effect moving two specific categories of marijuana, FDA-approved marijuana drug products and marijuana covered by a state medical marijuana license, from Schedule I to Schedule III. Recreational and adult-use marijuana remain Schedule I. A separate, broader DEA hearing considering full rescheduling ran June 29 through July 15, 2026. The article has been corrected to reflect the actual sequence and, critically, to correct the 280E section, which understated how narrow the relief that has actually taken effect is.

The cannabis rescheduling story has been dominated by a single number: 280E. Under schedule I classification, cannabis operators cannot deduct ordinary business expenses for federal tax purposes, producing effective tax rates north of 70% for many MSOs. A partial rescheduling has already taken effect, and it makes 280E inapplicable to a narrower slice of the industry than most coverage, including this piece’s original version, assumed. Treating that relief as sweeping misreads what actually changed, and what is still pending.

What actually happened, and what did not

On April 28, 2026, a DEA final order moved two specific categories of marijuana from Schedule I to Schedule III: drug products containing marijuana that have received FDA approval, and marijuana subject to a state-issued medical marijuana license. Everything else, recreational and adult-use marijuana, unlicensed product, bulk marijuana and extract not tied to an FDA-approved product or a qualifying medical license, remains Schedule I. The order used the Attorney General’s treaty-compliance authority under the Single Convention on Narcotic Drugs, which let it take effect immediately rather than through standard notice-and-comment rulemaking.

At the same time, DEA withdrew its prior 2024 rulemaking on broader marijuana rescheduling and opened a new expedited administrative hearing to consider whether marijuana more generally, including recreational marijuana, should also move to Schedule III. That hearing ran from June 29 through no later than July 15, 2026. Its outcome, not the April order, is what would extend rescheduling to the adult-use market that most large MSOs actually operate in.

Research access

Schedule I status has structured cannabis research the way it has structured psychedelic research: through DEA Form 225, the standard registration required for controlled-substance research across Schedules II through V, and through a historically narrow legal supply, for decades effectively limited to a single federally contracted grower whose product was widely criticized as unrepresentative of what patients and consumers actually use. The April 28 order eases both constraints for the categories it covers. It establishes an expedited DEA registration pathway for entities holding a state medical marijuana license, and it builds on an earlier 2026 rule change permitting registered researchers to source cannabis directly from a state-licensed dispensary rather than the old single-source arrangement. Research tied to recreational-market product, or product outside a qualifying medical license, has not yet benefited from either change and remains subject to the older, narrower registration and sourcing regime pending the broader rescheduling hearing’s outcome. Separately, any research supporting a specific therapeutic claim still requires an FDA Investigational New Drug application, with the same clinical trial design, safety monitoring, and Chemistry, Manufacturing, and Controls requirements that applied before rescheduling. Rescheduling has eased registration and fixed part of the sourcing bottleneck. It left the clinical evidentiary bar exactly where it was.

FDA pathway access

This is the part of the original thesis rescheduling has already delivered on, at least for the category it covers. An FDA-approved marijuana drug product is now, by definition, a Schedule III product, since the order moved exactly that category. This is the door cannabinoid pharma companies, GW Pharmaceuticals’ Epidiolex was the proof of concept, have been positioned to walk through, and it is now open rather than pending. For state-licensed operators without an FDA-approved product, the pathway is unchanged: filing an IND application on a specific cannabinoid formulation for a specific indication is the same process it was before April 28, just aimed at a schedule the eventual approved product will already sit in rather than one it would need to escape.

The strategic question for operators is the same one this piece originally posed: remain a CPG company selling adult-use product through state-licensed dispensaries, or build a pharmaceutical pipeline on top. That question is now sharper, since the pharmaceutical route has a clearer scheduling destination than it did before.

Capital markets and the 280E correction

This is where the original version of this piece was least accurate, and it is worth being direct about the correction. Section 280E’s deduction disallowance applies to trafficking in a Schedule I or II substance. The April 28 order removed that classification for state-licensed medical marijuana. It did not remove it for recreational or adult-use marijuana, which is Schedule I today and remains so pending the broader hearing.

The practical consequence is that 280E relief, where it applies, applies to the medical-license portion of an operator’s business, not automatically to the whole enterprise. For an operator licensed and selling in both medical and adult-use channels under the same footprint, legal guidance published around the order’s effective date describes the application of 280E to that mixed revenue as genuinely unresolved, with taxpayers advised to consult their own tax counsel rather than assume relief extends across the business. Most large multi-state operators, including the names in this piece, generate the substantial majority of their revenue from adult-use sales in states like Illinois, New York, New Jersey, and Massachusetts. For those operators, the 280E relief that has already taken effect reaches a minority share of their business at most, not the “arithmetic is real and substantial” outcome the original framing implied as a near-term event.

The broader capital markets constraint, institutional lending and major exchange listings, is unchanged by the April order and was never specific to 280E. Major US banks still will not lend to cannabis operators at scale, and the largest MSOs still trade on the Canadian Securities Exchange with US OTC listings rather than NYSE or NASDAQ. Whether the broader rescheduling hearing’s outcome changes that calculus is a live, open question rather than a settled one.

What comes next

The June 29 to July 15 hearing is where the rest of this story is decided. If the broader rescheduling proceeds, adult-use marijuana would move to Schedule III alongside the categories already rescheduled, and the 280E relief this piece originally described as imminent would finally apply to the revenue base that actually drives MSO valuations. If it does not, or is narrowed, the partial April order stands as the ceiling on federal relief for the foreseeable future, and the operators most exposed to adult-use revenue remain the operators least helped by what has happened so far.

Disclosure: Behavioral Wire’s editor holds no positions in any covered cannabis equities. See full disclosures.